JM1-24-3

JM1-24-3 (0.001-10 μg/mL) binds dose-dependently to live A375, A2058, and WM266-4 melanoma cells, with significantly stronger binding to highly metastatic A2058 and WM266-4 cells than to low metastatic A375 cells^[1].
JM1-24-3 (0.001-10 μg/mL) binds dose-dependently to A375, A2058, and WM266-4 melanoma cell lysates, with significantly stronger binding to highly metastatic A2058 cell lysates than to WM266-4 or low metastatic A375 cell lysates^[1].
JM1-24-3 binds to recombinant MUC18 with a high affinity (K_D = 1.60E-09)^[1].
JM1-24-3 (0.001-1 μg/mL) binding to WM266-4 melanoma cells is partially dependent on N-linked glycosylation of MUC18, as tunicamycin treatment (3.0 μg/mL; 24 h) reduces binding by 40.7%^[1].
JM1-24-3 (1 h, 6 h for RPPA; 0.5-24 h for WB) binding to MUC18 on WM266-4 melanoma cells modulates downstream signaling pathways, including time-dependent reduction of p-AKT (Ser473) and p-mTOR (Ser2448) phosphorylation, and alters expression of key cancer-associated proteins^[1].
JM1-24-3 (150 μg/mL; 7 days) inhibits proliferation of A375, A2058, and WM266-4 melanoma cells by 52%, 76%, and 46% respectively after 7 days of incubation^[1].
JM1-24-3 (150 μg/mL; 24 h) inhibits migration of WM266-4 melanoma cells by 58% after 24 h of incubation^[1].
JM1-24-3 (150 μg/mL) inhibits invasion of WM266-4 melanoma cells by 52%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.